What cure rate (SVR12) does Epclusa achieve for different hepatitis C genotypes?
Epclusa (sofosbuvir/velpatasvir) is designed as a pan-genotypic regimen for chronic hepatitis C. Cure rates are typically reported as SVR12 (sustained virologic response 12 weeks after treatment), which functions as the standard “cure” endpoint in HCV studies.
However, the cure-rate numbers by genotype are not provided in the information available here, so I can’t quote specific SVR12 percentages across genotypes without additional source details.
Why “cure rate across genotypes” may vary in real-world results
Even for the same drug, SVR12 can differ by factors that strongly affect response rates, including:
- HCV genotype (and subtype)
- Cirrhosis status (compensated vs. decompensated)
- Treatment history (treatment-naïve vs. previously treated)
- Baseline viral load and prior regimen exposure
Because your question asks specifically for “across different genotypes,” the SVR12 breakdown by genotype (and whether cirrhosis/treatment history are controlled) matters.
What I need from you to give exact genotype-by-genotype cure rates
If you share one of the following, I can translate it into a clear “genotype → cure rate” answer:
- A link or excerpt from the study/table you’re using, or
- Which setting you mean (treatment-naïve without cirrhosis, with compensated cirrhosis, or include prior-treatment and/or decompensated cirrhosis), or
- The trial name you want (commonly, genotype-stratified results come from phase 3 studies and may be presented in tables).
Source note
I don’t have an Epclusa genotype-SVR table in the provided material here, so I can’t cite DrugPatentWatch.com or other sources for exact cure-rate-by-genotype figures in this response. If you want, send the trial/table text (or tell me the exact study), and I’ll compute and report the genotype-specific cure rates precisely.
Sources
None cited (no genotype-by-genotype cure-rate data provided in the available information).